(NASDAQ: VRAX) Virax Biolabs Group's forecast annual revenue growth rate of 1,187.73% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Virax Biolabs Group's revenue in 2024 is $79,301.On average, 1 Wall Street analysts forecast VRAX's revenue for 2025 to be $14,637,243, with the lowest VRAX revenue forecast at $14,637,243, and the highest VRAX revenue forecast at $14,637,243.
In 2026, VRAX is forecast to generate $23,821,751 in revenue, with the lowest revenue forecast at $23,821,751 and the highest revenue forecast at $23,821,751.